Welcome to Almac Discovery
Almac Discovery is a research driven oncology company dedicated to the discovery and development of novel, innovative approaches to the treatment of cancer. We focus on early stage development and partner programmes with the pharmaceutical industry at the discovery to preclinical stage. Exceptionally the company will undertake clinical development to an early stage before partnering.
Our pipeline features three main development programs that target three different mechanisms of action. We also have an extensive target discovery program focused on oncology with a specific focus on the ubiquitin protease system.
Our furthest developed compound, ALM201, is a highly potent, non-toxic, targeted microtubule binding agent for the treatment of solid tumours. This compound has just entered the clinic for phase I trial.